Sign Out
In the in vitro human liver microsome test, albuvirtide was demonstrated not a CYP450 enzyme inhibitor, and had no significant inhibition effect on the activity of human liver microsomal enzymes CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4.
In the in vitro anti-HIV-1 combination therapy, albuvirtide had synergistic effect with zidovudine (AZT) and saquinavir (SQV), and additive effect with efavirenz (EFV) and enfuvirtide (T20).
Combination of AIKENING and lopinavir/ritonavir (LPV/r) did not change the pharmacokinetics profile of albuvirtide, the in vivo exposure to LPV/r was reduced, and no dose adjustments are needed.
Continue with Google